Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

S4 Capital's profit outlook unchanged despite revenue hit

(Sharecast News) - Shares in Martin Sorrell's S4 Capital rose on Wednesday despite the digital marketing agency and tech services firm cutting its revenue guidance for the full year, as the company held on to its targets to keep profits flat. The company, which had previously said it expected net revenues and operational EBITDA to be both unchanged on 2024, now forecasts a low-single-digit decline on the top line, with falls in marketing services and technology services.

The latter is still being affected by revenue reductions by a major client, but S4 said this effect will "cycle out" in the second half of the year.

Nevertheless, like-for-like operational EBITDA is still expected to be "broadly similar" to 2024, with a higher second-half weighting than last year. This reflects the timing of revenue from significant new business wins, particularly with General Motors, Amazon and T-Mobile, the company said.

In an AGM statement to shareholders, Martin Sorrell said that business has been affected by "volatile global macroeconomic conditions" over 2025 so far. "As a result, clients remain generally cautious given the uncertainty, with technology clients, which account for almost half our revenue, in particular, continuing to prioritise capital expenditure on expanding AI capacity," he said.

"We will continue to focus on our cost base and will take further action to support profitability, if necessary. We expect an improved performance in the second half of the year and a greater second half weighting than in the prior year, enhanced by the phasing of new business revenue, including wins already secured."

Shares were up 5% at 27.04p by 0840 BST, following a 20% drop in the stock so far this year.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.